Primary Surgery or Interval Debulking for Advanced Epithelial Ovarian Cancer: Does It Matter?

被引:26
|
作者
Markauskas, Algirdas [1 ]
Mogensen, Ole [1 ]
Christensen, Rene dePont [2 ]
Jensen, Pernille Tine [1 ]
机构
[1] Odense Univ Hosp, Dept Obstet & Gynaecol, DK-5000 Odense C, Denmark
[2] Univ Southern Denmark, Res Unit Gen Practice, Odense, Denmark
关键词
Debulking surgery; Epithelial ovarian cancer; Surgical complexity; Postoperative morbidity; Survival; NEOADJUVANT CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; QUALITY; RISK;
D O I
10.1097/IGC.0000000000000241
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the present study was to investigate the surgical complexity, the postoperative morbidity, and the survival of the women after primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) for advanced epithelial ovarian cancer. Materials and Methods: We consecutively included all patients who underwent debulking surgery at our institution between January 2007 and December 2012 for stages IIIc and IV of epithelial ovarian cancer. Results: Of the 332 patients included, 165 (49.7%) underwent PDS, and 167 (50.3%) had NACT-IDS. Complete intraperitoneal cytoreduction was achieved in 70.9% after PDS and in 59.9 % after NACT-IDS. Residual disease of greater than 1 cm was left in 18.5% and 27.5% after PDS and NACT-IDS, respectively. Compared with NACT-IDS, PDS was associated with higher surgical complexity (P < 0.001), longer operating time (P < 0.001), greater blood loss (P < 0.001), longer hospitalization (P = 0.001), and a higher rate of major postoperative complications (26.7% vs 16.8%). No statistical difference in the median overall survival (OS) was found between the patients having complete cytoreduction and residual disease of 1 cm or less after NACT-IDS. Furthermore, no statistical difference in the median OS was found between the patients with macroscopic residual disease (<= 1 vs >1 cm) after NACT-IDS. Patients with residual disease of greater than 1 cm after PDS had a median OS of 15 months. Conclusions: We suggest that NACT-IDS may be a better treatment alternative for the group of highly selected women not suitable for PDS, where expected suboptimal cytoreduction does not have any appreciable survival benefit and exposes them for unnecessary risks. A substantial number of women who receive either PDS or NACT-IDS have greater than 1 cm of tumor tissue left after the operation. These women probably have no survival benefit from the operation, and future studies should focus on how to select these women preoperatively.
引用
收藏
页码:1420 / 1428
页数:9
相关论文
共 50 条
  • [21] RETROSPECTIVE COMPARISON BETWEEN PRIMARY AND INTERVAL DEBULKING SURGERY FOR ADVANCED EPITHELIAL OVARIAN CANCER: A SINGLE INSTITUTION EXPERIENCE
    Garbi, A.
    Aletti, G.
    Messori, P.
    Zanagnolo, V.
    Achilarre, M. T.
    Bocciolone, L.
    Landoni, F.
    Volpi, L.
    Maggioni, A.
    Colombo, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 699 - 699
  • [22] RETROSPECTIVE COMPARISON BETWEEN PRIMARY AND INTERVAL DEBULKING SURGERY FOR ADVANCED EPITHELIAL OVARIAN CANCER: A SINGLE INSTITUTION EXPERIENCE
    Garbi, A.
    Colombo, N.
    Messori, P.
    Aletti, G.
    Zanagnolo, V.
    Achilarre, M.
    Landoni, F.
    Bocciolone, L.
    Maggioni, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1348 - 1348
  • [23] Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis
    Ghirardi, V
    Moruzzi, M. C.
    Bizzarri, N.
    Vargiu, V.
    D'Indinosante, M.
    Garganese, G.
    Pasciuto, T.
    Loverro, M.
    Scambia, G.
    Fagotti, A.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (01) : 209 - 213
  • [24] Does Modality of Adjuvant Chemotherapy After Interval Surgical Debulking Matter in Epithelial Ovarian Cancer?
    Al Mutairi, Nashmia Joudallah
    Le, Tien
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (03) : 461 - 467
  • [25] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Ce Bian
    Kui Yao
    Li Li
    Tao Yi
    Xia Zhao
    Archives of Gynecology and Obstetrics, 2016, 293 : 163 - 168
  • [26] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Bian, Ce
    Yao, Kui
    Li, Li
    Yi, Tao
    Zhao, Xia
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 293 (01) : 163 - 168
  • [27] Differences in Patterns of Recurrence Between Primary and Interval Debulking Surgery for Advanced Ovarian Cancer
    Mitsopoulos, Vasileios
    Innamaa, Anni
    Lippiatt, Jonathan
    Collins, Sarah
    Biliatis, Ioannis
    ANTICANCER RESEARCH, 2022, 42 (04) : 2003 - 2008
  • [28] Operative morbidity following primary and interval debulking surgery for advanced ovarian cancer.
    Rose, PG
    Nerenston, S
    Brady, MF
    Clarke-Pearson, D
    Olt, G
    Rubin, SC
    Moore, DH
    Small, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 451S - 451S
  • [29] Primary or Interval Debulking Surgery in Advanced Ovarian Cancer: a Personalized Decision—a Literature Review
    Delphine Hudry
    Stéphanie Bécourt
    Giovanni Scambia
    Anna Fagotti
    Current Oncology Reports, 2022, 24 : 1661 - 1668
  • [30] PRIMARY VS INTERVAL DEBULKING SURGERY FOR ADVANCED EPITHELIAL OVARIAN CANCER: SURVIVAL OUTCOMES FROM A TERTIARY GREEK CENTRE
    Vlachos, D-E
    Haidopoulos, D.
    Thomakos, N.
    Kalogeris, E.
    Rodolakis, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A537 - A537